This study aimed to establish the relationship between antral follicle count (AFC), the time of puberty, and ovarian response in Nelore heifers subjected to timed-AI (TAI) protocols. Prepubescent Nelore heifers (Bos indicus; n = 30) were examined by transrectal ultrasound and videos of the ovaries were recorded for later CFA (≥ 3 mm). After AFC, heifers were divided into 2 groups, low and high AFC and then further ultrasonic ovarian assessments were performed to determine the onset of puberty. Once puberty was established in all heifers, they were submitted to an FTAI protocol. There were no differences (P > 0.1) between groups on the time of puberty, ovulation rate, the proportion of heifers that expressed estrus, and on preovulatory follicle diameter. However, heifers with low AFC had a smaller ovarian area in the prepubertal period (4.36 ± 0.3 vs. 5.65 ± 0.2 cm2) and, in the FTAI, they had the moment of estrus (48 ± 0.0 vs. 58.5 ± 3.1 h) and earlier ovulation (60 ± 1.8 vs. 72.6 ± 4.7 h) compared to heifers with high AFC (P < 0.05). In addition, heifers in the low AFC group had a higher (P = 0.05) pregnancy per AI (76.9%, 10/13) than the high AFC group (29.4%, 5/17). In this study, heifers with low AFC had the moment of ovulation anticipated and greater pregnancy per AI compared to heifers with high AFC.
The aims of this study were to determine (1) the association between Doppler vascularisation scores (DVS) of the preovulatory follicle (POF) and fertility of beef cows submitted to timed AI (TAI) and (2) whether cows with low DVS benefit from a gonadotrophin-releasing hormone (GnRH) treatment at TAI. Multiparous lactating Nelore cows (Bos indicus; n=69) from a commercial beef farm in the state of Rondônia, Brazil, were enrolled in this study. Cows received 2mg of oestradiol benzoate intramuscularly (Bioestrogen, Biogénesis Bagó) and an intravaginal progesterone-releasing device (1.9g of progesterone; controlled internal drug release, CIDR) to synchronise follicular wave emergence on Day 0. The CIDR device was removed and cows were treated with 150μg of D-cloprostenol intramuscularly (prostaglandin F2α analogue; Croniben), 1mg of oestradiol cypionate intramuscularly, and 300IU of equine chorionic gonadotrophin (Novormon) intramuscularly on Day 8. Cows were then painted with a tail chalk marker to identify those displaying oestrus. All cows were submitted to TAI 48h after CIDR removal. At TAI, occurrence of oestrus was recorded and all cows were examined using transrectal ultrasonography. Blood flow of the POF was evaluated using colour Doppler imaging. Colour Doppler signals present on the follicular wall were subjectively scored using a 1-to-4 scale (1=absence or very low blood flow, and 4=intense blood flow detected on most of the follicular wall surface) adapted from Ginther (2007Ultrasonic Imaging and Animal Reproduction: Color-Doppler Ultrasonography, pages 87-114). Then, cows were divided into three groups according their DVS of the POF: (1) high DVS (DVS ≥3; n=36), (2) low DVS (DVS <3; n=16), and (3) low DVS (DVS <3; n=17) plus a GnRH treatment at TAI. The diameter of the POF was analysed using analysis of variance (PROC GLIMMIX of SAS; SAS Institute Inc.), and the means were compared among groups using Tukey's test. The proportion of cows that displayed oestrus and pregnancy rates was analysed using chi-square test. Cows in the high-DVS group had a larger POF than cows in the low-DVS and low-DVS-GnRH groups (13.2±0.2, 11.7±0.5, and 12.2±0.4, respectively; P<0.05). The proportion of cows that displayed oestrus was greater (P<0.05) in the high-DVS group (72%, 26/36) than in the low-DVS (37.5%, 6/16) or low-DVS-GnRH (53%, 9/17) groups. Finally, greater (P<0.05) pregnancy rates were observed in cows from the high-DVS (47.2%; 17/36) and low-DVS-GnRH (52.9%; 9/17) groups than in cows from the low-DVS group (18.7%; 3/16). The preliminary results from this study demonstrated that diameter of POF is positively associated with DVS. Moreover, cows that presented POF with higher DVS are more likely to become pregnant, and the administration of GnRH to females with low DVS can increase the fertility of beef cows submitted to TAI protocols. This study received funding support from Embrapa (MP1/PC3 project no. 01.03.14.011.00.00) and from CNPq (universal project no. 407307/2016-8).
This study aimed to compare the biological activity of the uterus and the metabolism between primiparous and multiparous crossbred dairy cows. Eighteen crossbred dairy cows (B. indicus x B. taurus) were divided by parity order into primiparous (n = 8), and multiparous (n = 10) cows. These cows were evaluated from parturition to 50 days in milk (DIM) for metabolic and reproductive variables. Also, uterine tissue was collected using the cytobrush technique to assess the proportion of polymorphonuclear cells and abundance of transcripts of genes associated with inflammation and receptivity. Multiparous cows had greater milk production (P = 0.04). Primiparous cows had a higher (P ≤ 0.05) relative abundance of IL-6, PTCH2, and PGR mRNA. In contrast, Multiparous cows had a higher relative abundance of IL-10 mRNA. The proportion of primiparous cows ovulating from calving to 50 DIM tended (P = 0.08) to be greater. Overall, the findings indicated that parity does not significantly affect energy metabolism and that multiparous cows have lower uterine inflammatory response associated with lower relative expression of IL-6 and higher relative expression of IL-10. These results led us to conclude that parity has little effect on the puerperium of crossbred dairy cows. Moreover, crossbred dairy cows were considered healthy by 50 DIM; however, further field studies with larger numbers of animals should be performed to define an optimal voluntary waiting period for crossbred dairy cows raised in the Amazon Biome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.